---
document_datetime: 2024-09-05 09:42:35
document_pages: 21
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/arava-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: arava-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 15.9655874
conversion_datetime: 2025-12-26 20:49:14.828758
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Arava

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                         | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                                   |
|----------------------|---------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0086              | A.6 - Administrative change - Change in ATC Code/ATC Vet Code | 06/08/2024                          |                                             | SmPC and PL                      |                                                                                                                                           |
| PSUSA/1837/ 202309   | Periodic Safety Update EU Single assessment - leflunomide     | 30/05/2024                          | 01/08/2024                                  | SmPC and PL                      | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/1837/202309. |
| IA/0085              | B.I.b.1.d - Change in the specification parameters            | 23/04/2024                          | n/a                                         |                                  |                                                                                                                                           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|           | and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter)                                                                                                                                                                                                                                    |            |            |             |                                                                                                                                                                                                                                                       |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0084   | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                                                                                                                                                                                                                                                                    | 28/02/2024 | n/a        |             |                                                                                                                                                                                                                                                       |
| N/0082    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                    | 26/06/2023 | 01/08/2024 | PL          |                                                                                                                                                                                                                                                       |
| IB/0081   | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                                                       | 31/08/2022 | n/a        |             |                                                                                                                                                                                                                                                       |
| IB/0079   | C.I.3.z - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Other variation                                                                                                                                                                                                      | 25/03/2022 | 12/08/2022 | SmPC and PL | Update of Sections 4.4 and 4.8 of the SmPC with information on skin ulcer following PRAC recommendation issued for the Post-Authorisation Measure EMEA/H/C/000235/LEG/058.1 for leflunomide containing products. The PL has been updated accordingly. |
| IA/0080/G | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder | 25/02/2022 | n/a        |             |                                                                                                                                                                                                                                                       |

<div style=\"page-break-after: always\"></div>

|                    | intermediate used in the manufacture of the AS or manufacturer of a novel excipient                                        |            |            |                  |                                   |
|--------------------|----------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------|-----------------------------------|
| N/0078             | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                           | 09/12/2021 | 12/08/2022 | PL               |                                   |
| IG/1386            | A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release | 03/08/2021 | 12/08/2022 | Annex II and PL  |                                   |
| PSUSA/1837/ 202009 | Periodic Safety Update EU Single assessment - leflunomide                                                                  | 06/05/2021 | n/a        |                  | PRAC Recommendation - maintenance |
| N/0075             | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                           | 07/10/2020 | 12/08/2022 | PL               |                                   |
| N/0074             | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                           | 13/02/2020 | 12/08/2022 | PL               |                                   |
| PSUSA/1837/ 201709 | Periodic Safety Update EU Single assessment - leflunomide                                                                  | 12/04/2018 | n/a        |                  | PRAC Recommendation - maintenance |
| N/0073             | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                           | 09/04/2018 | 30/07/2018 | Labelling and PL |                                   |
| IG/0823            | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                             | 14/07/2017 | 30/07/2018 | SmPC and PL      |                                   |
| PSUSA/1837/ 201609 | Periodic Safety Update EU Single assessment - leflunomide                                                                  | 06/04/2017 | n/a        |                  | PRAC Recommendation - maintenance |

<div style=\"page-break-after: always\"></div>

| IA/0069            | B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter)                                                                                                                                   | 03/06/2016   | n/a        |                       |                                                                                                                                                                                                                                |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| N/0068             | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                      | 19/05/2016   | 15/09/2016 | PL                    |                                                                                                                                                                                                                                |
| PSUSA/1837/ 201509 | Periodic Safety Update EU Single assessment - leflunomide                                                                                                                                                                                                                                                                                             | 14/04/2016   | n/a        |                       | PRAC Recommendation - maintenance                                                                                                                                                                                              |
| IG/0635            | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                        | 14/12/2015   | 15/09/2016 | SmPC and PL           |                                                                                                                                                                                                                                |
| WS/0816/G          | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation | 22/10/2015   | 15/09/2016 | SmPC, Annex II and PL |                                                                                                                                                                                                                                |
| PSUSA/1837/ 201409 | Periodic Safety Update EU Single assessment - leflunomide                                                                                                                                                                                                                                                                                             | 10/04/2015   | n/a        |                       | PRAC Recommendation - maintenance                                                                                                                                                                                              |
| WS/0560/G          | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.                                                                                                                                                                                               | 25/09/2014   | 07/11/2014 | SmPC and PL           | With the development of teriflunomide, the main active metabolite of leflumonide, as a drug for the treatment of multiple sclerosis, several interaction studies were performed according to current standards. This variation |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| This worksharing includes 9 type II variations per product grouped as follows: -Type II variation, C.I.4 : Update of sections 4.3 and 4.4 of the SmPC contraindicating and including a warning on teriflunamide the active metabolite of leflunomide; -2 Type II variations, C.I.4 : Update of section 4.5 of the SmPC for leflunomide related to the study reports HWA486/1032/001 (interaction cimetidine) and -HWA486/2F0.1 (interaction with methotrexate); - 6 Type II variations, C.I.4 : Update of section 4.5 of the SmPC for teriflunomide related to the following Study reports INT11697-INT11720-INT12503- INT12500-INT10564-INT6040. In addition and following CHMP request section 4.4 of the SmPC was updated to include a warning for patients to be evaluated for tuberculosis before starting treatment with leflunomide. The PL was revised to reflect the above warnings and interactions. Furthermore, the MAH took the opportunity of this worksharing to reflect the interaction studies in the RMP and to include DRESS syndrome in the RMP as requested by PRAC. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance   | hamonised the results of the interaction studies of the main metabolite with the parent drug leflumonide. Caution and intensified monitoring is recommended for combined use of leflunomide and a broad range of products since the plasma levels may be increased by the concurrent use of leflumonide. The benefit/risk balance of leflumonide remains positive, considering that interactions could be controlled by dose adjustments. Co administration of teriflunomide with leflunomide is not recommended, as leflunomide is the parent compound of teriflunomide.   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|         | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance   |            |            |             |                                                                                                                                                                                                                                                                                     |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IG/0454 | C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 17/07/2014 | n/a        |             |                                                                                                                                                                                                                                                                                     |
| WS/0526 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update of sections 4.4 and 4.8 of the SmPC in order                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 22/05/2014 | 07/11/2014 | SmPC and PL | 14 cases of DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms) have been retrieved. 10 cases are reports from literature articles and 4 are spontaneous. Of the 14 cases, 7 provide insufficient or inconclusive information. The remaining 7 spontaneous and literature |

<div style=\"page-break-after: always\"></div>

|                    | to add a warning and update the safety information on DRESS (drug reaction with eosinophilia and systemic symptoms). The section 2 and 4 of the Package Leaflet were proposed to be updated accordingly. In addition, the MAH took the opportunity to update the list of local representatives for Finland, Malta, Sweden and United Kingdom in the Package Leaflet. C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation   |            |            |             | cases of DRESS have (strong) suggestive evidence and strong temporal association with leflunomide (2 'definite' and 5 'possible' cases according to the RegiSCAR criteria). The product information has therefore been updated to include that cases of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) have been reported in patients treated with leflunomide. The MAHs of generic products containing leflunomide will update their product information in line with that of the reference product.   |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/1837/ 201309 | Periodic Safety Update EU Single assessment - leflunomide                                                                                                                                                                                                                                                                                                                                                                                                             | 10/04/2014 | n/a        |             | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| IA/0060            | B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                                                                                                          | 20/02/2014 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| IG/0354            | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                        | 05/11/2013 | 07/11/2014 | SmPC and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| IG/0314            | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                        | 08/07/2013 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| WS/0271            | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update of sections 4.4 and 4.8 of the SmPC to add cutaneous lupus erythematosus, pustular psoriasis or worsening psoriasis and warn physicians about these                                                                                                                                                              | 15/11/2012 | 18/12/2012 | SmPC and PL | Based on published clinical trial data and single case reports in the scientific literature, a possible causal association of leflunomide treatment with worsening of underlying psoriasis and pustular psoriasis is strongly suggested by two cases identified from the company global pharmacovigilance database reporting positive rechallenge after reintroduction of leflunomide. No similar published                                                                                                            |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| skin reactions. The PL is being updated accordingly. Furthermore, the list of local representatives in section 6 of the PL is being updated. C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre- clinical, clinical or pharmacovigilance data   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|           |                                                                                                                                                                                                                                                                                                                                                                                        |            |            |                                  | history.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0055/G | This was an application for a group of variations. B.I.a.3.b - Change in batch size (including batch size ranges) of AS or intermediate - Downscaling B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                                                                                                 | 19/03/2012 | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| II/0050   | Update of section 4.4 of the SmPC to strengthen the warning regarding peripheral neuropathy. The PIL is updated accordingly. Furthermore, changes relating to the implementation of the latest QRD template are being proposed. C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre- clinical, clinical or pharmacovigilance data | 16/02/2012 | 19/03/2012 | SmPC, Annex II, Labelling and PL | Peripheral neuropathy (PNP) has been associated with autoimmune diseases like RA; however, there are also signals from the literature and the Company's Safety Database indicating a causal relationship between the occurrence of PNP and the use of leflumonide. From the submitted data it may be concluded that leflunomide is an independent risk factor for PNP besides other risk factors and it is considered relevant to inform prescribers regarding this risk. Based on the available safety data from case reports and several non-randomized cohort studies, a warning regarding the association of leflunomide use and PNP has been added and the frequency of PNP in section 4.8 has been updated to 'common'. |
| IG/0147/G | This was an application for a group of variations. C.I.9.c - Changes to an existing pharmacovigilance system as described in the DDPS - Change of the back-up procedure of the QPPV C.I.9.e - Changes to an existing pharmacovigilance system as described in the DDPS - Changes in the major contractual arrangements with other persons                                              | 29/02/2012 | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |

<div style=\"page-break-after: always\"></div>

|         | or organisations involved in the fulfilment of pharmacovigilance obligations and described in the DD C.I.9.f - Changes to an existing pharmacovigilance system as described in the DDPS - Deletion of topics covered by written procedure(s) describing pharmacovigilance activities C.I.9.h - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of the pharmacovigilance system   |            |            |      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0049 | Update of section 4.4 of the SmPC regarding the risk of leflunomide use in combination with biologicals following the CHMP assessment of the COLEBI study. C.I.3.b - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under Article 45/46, or amendments to reflect a Core SPC - Change(s) with new additional data submitted by the MAH                                                        | 22/09/2011 | 10/11/2011 | SmPC | The COLEBI study is a retrospective observational study comparing RA patients who were treated with a combination of leflunomide + TNF-inhibitor with those who were treated with a combination of MTX + TNF-inhibitor. Following the assessment of the results of the COLEBI study, which have been submitted as a follow-up measure, the MAH was asked to update the warning section of the SmPC to with regard to the combined use of leflunomide and TNF-Inhibitors. Furthermore, the warning section has been updated regarding the risk of tuberculosis and the need for appropriate testing. |
| II/0047 | Update of sections 4.2 and 5.1 of the SmPC to reflect the outcome of the clinical study R01143 (LEADER) regarding the use of a loading dose, as requested by the CHMP. C.I.3.b - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under Article                                                                                                                                                 | 23/06/2011 | 10/08/2011 | SmPC | The MAH has conducted a post-marketing study (R01143, LEADER) in which two initial dosing regimen were used, 121 DMARD-naive patients with early RA were randomized to receive either the 20 mg or 100 mg starting dose in a double-blind, double-dummy fashion, followed by an open- label maintenance period of 3 months during which 20mg/d where administered. The ACR20 response rate at 90 days (primary endpoint) was statistically significantly higher in                                                                                                                                  |

<div style=\"page-break-after: always\"></div>

|         | 45/46, or amendments to reflect a Core SPC - Change(s) with new additional data submitted by the MAH                                                                                                                                                                                                                                                                                                                                                                                                              |            |            |                       | the flat-dose group compared to the loading dose group. There were, however, no significant differences for any of the secondary efficacy parameters, such as ACR50 or DAS28 response and, also considered the small sample size, superiority of flat dosing regimen above the 100 mg loading dose cannot be concluded. However, there appears to be no loss of clinical response in the flat dose regimen as compared to the loading dose regimen. The incidence of gastrointestinal AEs and of elevated liver enzymes reported as adverse events tended to be higher during the earlier phases of treatment in patients receiving the loading dose of 100 mg leflunomide. Overall, the safety data obtained were consistent with the known safety profile of leflunomide.   |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IG/0091 | C.I.9.h - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of the pharmacovigilance system                                                                                                                                                                                                                                                                                                                            | 05/07/2011 | n/a        |                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| II/0048 | Update of 4.4 of the SmPC to amend the warning for interstitial lung disease (ILD) as requested by the CHMP. The PIL was revised accordingly. In addition the description of the risk of teratogenicity in the PIL was aligned with the educational material agreed in August 2010. Further updates concerns the Annex IIB regarding DDPS / RMP version and the implementation of the latest QRD template. C.I.3.b - Implementation of change(s) requested following the assessment of an USR, class labelling, a | 17/03/2011 | 18/04/2011 | SmPC, Annex II and PL | Following a CHMP request, the MAH conduct a search of recent relevant literature on interstitial lung disease (IDL) in association with leflunomide treatment as a follow-up measure. Following the assessment of the information provided by the MAH, an update of section 4.4 of the SmPC was requested to highlight the increased risk in case of pre- existing IDL. Furthermore, the MAH has aligned the information on serious birth defects in the package leaflet with the Patient Sheet (educational material) of the EU- RMP.                                                                                                                                                                                                                                        |

<div style=\"page-break-after: always\"></div>

|           | 45/46, or amendments to reflect a Core SPC - Change(s) with new additional data submitted by the MAH                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |            |            |                        |                                                                                                            |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|------------------------------------------------------------------------------------------------------------|
| IG/0004/G | This was an application for a group of variations. C.I.9.a - Changes to an existing pharmacovigilance system as described in the DDPS - Change in the QPPV C.I.9.b - Changes to an existing pharmacovigilance system as described in the DDPS - Change in the contact details of the QPPV C.I.9.c - Changes to an existing pharmacovigilance system as described in the DDPS - Change of the back-up procedure of the QPPV C.I.9.d - Changes to an existing pharmacovigilance system as described in the DDPS - Change in the safety database C.I.9.h - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of | 06/05/2010 | n/a        | Annex II               |                                                                                                            |
| II/0046   | C.I.3.b - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under Article 45/46, or amendments to reflect a Core SPC - Change(s) with new additional data submitted by the MAH                                                                                                                                                                                                                                                                                                                                                                                                                                             | 18/02/2010 | 29/04/2010 | SmPC, Labelling and PL |                                                                                                            |
| II/0045   | Update of the Annex II with the new version number of the adopted DDPS (version 2.4) and the RMP                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 17/12/2009 | 27/01/2010 | Annex II               | The MAH has submitted an updated description of the Pharmacovigilance System and an RMP to harmonise these |

<div style=\"page-break-after: always\"></div>

|         | (version 1.3). Update of or change(s) to the pharmaceutical documentation                                                                                                                                                                                                                                                                                                                                                                                                                                    |            |            |                                  | documents with those recently approved for Leflunomide Winthrop. The documents are identical. The conditions for the marketing authorisation (Annex II) have also been updated in accordance with those agreed upon for Leflunomide Winthrop.                                                                                                                                                                                                                                                                                           |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0043 | Update of section 4.6 of the SPC based on conclusions from the OTIS study. This variation application is submitted further to the request of the CHMP following assessment of PSUR 19-20 for Arava, covering the period 11 Septmeber 2007 - 10 September 2008. The MAH has also taken the opportunity, for consistency with the SPC, to include minor changes in section 6 \"Further information\" of the package leaflet for the strengths 10 mg and 100 mg. Update of Summary of Product Characteristics and | 24/09/2009 | 28/10/2009 | SmPC and PL                      | The MAH was requested to update the SPC section 4.6 based on conclusions from the organisation of teratology information specialists (OTIS) study. In this study it was shown that there was no increased risk of malformations after exposure to leflunomide in the first three weeks of pregnancy and followed by a drug elimination procedure. Although reassuring for women who become inadvertently pregnant while taking leflunomide, these results are too limited to warrant the removal of the contraindication for pregnancy. |
| IA/0044 | IA_37_a_Change in the specification of the finished product - tightening of specification limits                                                                                                                                                                                                                                                                                                                                                                                                             | 11/08/2009 | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| R/0041  | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 23/04/2009 | 01/07/2009 | SmPC, Annex II, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| IA/0042 | IA_04_Change in name and/or address of a manuf. of the active substance (no Ph. Eur. cert. avail.)                                                                                                                                                                                                                                                                                                                                                                                                           | 11/03/2009 | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| IB/0039 | IB_25_a_01_Change to comply with Ph. - compliance with EU Ph. - active substance                                                                                                                                                                                                                                                                                                                                                                                                                             | 15/05/2008 | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |

<div style=\"page-break-after: always\"></div>

| IA/0040   | IA_05_Change in the name and/or address of a manufacturer of the finished product                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 23/04/2008   | n/a        | Annex II and PL                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0038   | Update of Summary of Product Characteristics, Labelling and Package Leaflet To align the Product Information to the latest EMEA/QRD template (version 7.2) and to amend the PL to reflect the results of the user testing. Furthermore, the Marketing Authorisation Holder took the opportunity to update Annex II to reflect the submission of yearly PSURs and to include the prescription status (\"Medicinal product subject to medical prescription\") on the label of the bottles. Update of Summary of Product Characteristics, Labelling and Package Leaflet | 24/01/2008   | 26/02/2008 | SmPC, Annex II, Labelling and PL | The Product Information was updated in order to be in line with the latest EMEA/QRD template (version 7.2). In this respect section 4.8 of the SPC was reviewed according to the current Guideline on Summary of Product Characteristics (October 2005) in order to describe the adverse reactions according to MedDRA system organ class and to rank them under headings of frequency using the convention as stated in the Guideline and in the EMEA/QRD template. Furthermore, the PL was updated to reflect the results of the user testing. Finally, the Marketing Authorisation Holder took the opportunity to update Annex II to reflect the submission of yearly PSURs and to include the prescription status (\"Medicinal product subject to medical prescription\") on the label of the bottles. |
| II/0034   | Update of section 4.8 of the SPC to include the adverse reaction \"renal failure\" (with unknown frequency). Section 4 of the PL was updated accordingly. Additionally, the Marketing Authorisation Holder took the opportunity to update the list of local representatives in section 6 of the PL and to replace \"cholestyramine\" with the INN name \"colestyramine\" in the SPC and PL. Update of Summary of Product Characteristics and Package Leaflet                                                                                                             | 20/09/2007   | 08/11/2007 | SmPC and PL                      | In the framework of the assessment of PSURs No 16 and 17, covering the period from 11 March 2006 to 10 March 2007, the CHMP requested the Marketing Authorisation Holder to provide a cumulative review for renal failure. A total of 139 cases were reported. The global exposure was more than 1 million patients per year. Although the reporting rate of renal failure remained rare, the CHMP noted that there were more than 100 reported cases for renal failure from which most were serious. Therefore, the CHMP concluded that a possible causal relationship between leflunomide and renal failure can not be excluded. Thus, sections 4.8 of the SPC and 4 of the PL were updated to include \"renal failure\", with unknown frequency.                                                        |

<div style=\"page-break-after: always\"></div>

|         |                                                                                                                                                                                                                                                                                                                                                                  |            |            |             | Additionally, the Marketing Authorisation Holder took the opportunity to update the list of local representatives in section 6 of the PL and to replace \"cholestyramine\" with the INN name \"colestyramine\" in the SPC and PL.                                                                                                                                                                                                                                                                                                                                                                                                   |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0037 | IB_14_b_Change in manuf. of active substance without Ph. Eur. certificate - new manufacturer                                                                                                                                                                                                                                                                     | 07/11/2007 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| IB/0036 | IB_14_b_Change in manuf. of active substance without Ph. Eur. certificate - new manufacturer                                                                                                                                                                                                                                                                     | 07/11/2007 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| IB/0035 | IB_30_b_Change in supplier of packaging components - replacement/addition                                                                                                                                                                                                                                                                                        | 17/10/2007 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| N/0033  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                 | 26/01/2007 | n/a        | PL          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| IA/0032 | IA_04_Change in name and/or address of a manuf. of the active substance (no Ph. Eur. cert. avail.)                                                                                                                                                                                                                                                               | 04/08/2006 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| II/0029 | This variation relates to an update of section 4.8 \"Undesirable effects\" of the Summary of Product Characteristics and section 4 \"Possible side effects\" of the Package leaflet for Arava to include \"cutaneous necrotizing vasculitis\" following a review of the available safety information. Update of Summary of Product Characteristics and Package Leaflet | 17/11/2005 | 10/01/2006 | SmPC and PL | Following the receipt of isolated postmarketing reports of necrotising cutaneous vasculitis, a cumulative search of the MAH's database was performed for vasculitis and specifically vasculitis necrotising. After the review of the available safety information, the MAH decided to amend the Company Core Data Sheet (CCDS) to include the description of the specific potential risk of 'cutaneous necrotizing vasculitis'. In line with this the MAH has proposed to amend the Summary of Product Characteristics and the Package leaflet to include \"necrotising cutaneous vasculitis\" as a very rare undesirable effect. |

<div style=\"page-break-after: always\"></div>

| IA/0031   | IA_01_Change in the name and/or address of the marketing authorisation holder                                                                                                                                                                                                                                                                                                                                                                                                         | 16/12/2005   | n/a        | SmPC, Labelling and PL   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|--------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0030   | IA_05_Change in the name and/or address of a manufacturer of the finished product                                                                                                                                                                                                                                                                                                                                                                                                     | 16/12/2005   | n/a        | Annex II and PL          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| II/0028   | This variation relates to an update of sections 4.2 \"Posology and method of administration\", 5.1 \"Pharmacodynamic properties\" and 5.2 \"Pharmacokinetic properties\" of the Summary of Product Characteristics to include the results of clinical studies in patients with polyarticular Juvenile Rheumatoid Arthritis (JRA). Consequent changes are proposed in section 3 \"How to take Arava\" of the Package Leaflet. Update of Summary of Product Characteristics and Package Leaflet | 13/10/2005   | 15/11/2005 | SmPC and PL              | Leflunomide, the active substance of Arava, was studied in a single multi-centre, randomised, double-blind, active- controlled trial in 94 patients (47 per arm) with polyarticular course Juvenile Rheumatoid Arthritis (JRA). Patients were 3-17 years of age with active polyarticular course JRA regardless of onset type and naive to methotrexate or leflunomide. In this trial, the loading dose and maintenance dose of leflunomide were based on three weight categories: children < 20 kg 100mg loading dose for 1 day followed by 10 mg every other day; children 20-40 kg: 100 mg loading dose for 2 days followed by 10 mg/day; children > 40 kg: 100 mg loading dose 3 days followed by 20 mg/day (the methotrexate dose was 0.5 mg/kg/week per os to a maximum of 25 mg/week). After 16 weeks treatment, the difference in response rates was statistically significant in favour of methotrexate for the JRA Definition of Improvement (DOI) = 30% (CI 95% : - 37.3 , -5.3; p=0.02) . This response was maintained during 48 weeks. The pattern of adverse events of leflunomide and methotrexate seems to be similar, but the dose used in lighter subjects resulted in a relatively low exposure (see below) which might have influenced safety data. These |

<div style=\"page-break-after: always\"></div>

|         |                                                                                                                                                                                                                                                                                                                                                                                 |            |            |             | recommendation in patients under 18 years. The pharmacokinetics of A771726, the active metabolite of leflunomide, following oral administration of leflunomide, have been investigated in 73 paediatric patients with polyarticular course JRA who ranged in age from 3 to 17 years. The results of a population pharmacokinetic analysis of these trials have demonstrated that paediatric patients with body weights = 40 kg have a reduced systemic exposure (measured by concentration at steady state) of A771726 relative to adult rheumatoid arthritis patients. Calculation via a pharmacokinetic model indicated that a leflunomide average steady state plasma concentration of about 34 g/ml will be obtained in pediatr   |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0027 | Update of section 4.8 \"Undesirable effects\" of the SPC to modify the frequency of severe infections including sepsis to rare, following the assessment of PSUR No. 10 and 11 (reporting period 12.03.2003- 11.03.2004) and FUM20.3. The Package Leaflet was updated in accordance with the changes to the SPC. Update of Summary of Product Characteristics and Package Leaflet | 27/07/2005 | 19/09/2005 | SmPC and PL | The CHMP agreed that proposed changes to the SPC adequately reflect the current post-marketing cumulative experience with exposure to Arava and the available knowledge on severe infections including sepsis following the use of Arava. Considering the above safety update to the Product Information, the CHMP considered that the benefit/risk assessment of Arava remained favourable. The CHMP agreed with the proposed amendments of the PL.                                                                                                                                                                                                                                                                                   |
| II/0026 | Update of sections 4.2 and 5.1 of the SPC following the CHMP assessment of study HWA 486/3012 on efficacy and safety of leflunomide 10 mg versus 20 mg daily doses in patients with active rheumatoid                                                                                                                                                                           | 21/10/2004 | 06/12/2004 | SmPC and PL | The CHMP agreed that the proposed wording of sections 4.2 and 5.2 of the SPC adequately reflect the data from the randomised, double-blind, parallel-group comparative trial of the efficacy and safety of leflunomide 10mg versus 20mg                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |

<div style=\"page-break-after: always\"></div>

|         | arthritis. Update of Summary of Product Characteristics and Package Leaflet                                                                                                                                                                                                                                                                                                         |            |            |                                  | daily doses in patients with active rheumatoid. The efficacy results of the 20 mg maintenance dose were more favourable, on the other hand, the safety results favoured the 10 mg daily maintenance dose. The recommended maintenance dose for rheumatoid arthritis is leflunomide 10 mg to 20 mg once daily. Patients may be started on leflunomide 10 mg or 20 mg depending on the severity (activity) of the disease. The CHMP agreed with the proposed amendments of the PL.   |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| R/0024  | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                             | 29/07/2004 | 13/10/2004 | SmPC, Annex II, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| II/0023 | Update of SPC sections 4.4 (Special warnings and special precautions for use) and 4.8 (Undesirable effects) to include a warning on interstitial pneumonia and to update the stated frequency for interstitial lung disease to \"rare\". Sections 2 and 4 of the Package Leaflet (PL) are amended accordingly. Update of Summary of Product Characteristics and Package Leaflet       | 22/04/2004 | 10/06/2004 | SmPC and PL                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| II/0022 | Update of the Summary of Product Characteristics sections 4.1 (Therapeutic indications), 4.2 (Posology and method of administration), 4.3 (Contraindications) and 5.1 (Pharmacodynamic properties) to extend the indication to psoriatic arthritis and include results from a multinational randomised, double-blind placebo controlled study in patients with psoriatic arthritis. | 24/03/2004 | 08/06/2004 | SmPC and PL                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

|         | The Package Leaflet has been amended accordingly. In addition, the MAH took the opportunity to update the adresses of Aventis EU affiliates and to add the list of local representatives for the 10 accession countries in section 6 of the Package Leaflet in accordance with EMEA/QRD templates. Extension of Indication                                                          |            |            |                 |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|
| IA/0025 | IA_05_Change in the name and/or address of a manufacturer of the finished product                                                                                                                                                                                                                                                                                                   | 19/04/2004 | n/a        | Annex II and PL |
| II/0021 | Update of Summary of Product Characteristics                                                                                                                                                                                                                                                                                                                                        | 22/10/2003 | 27/01/2004 | SmPC            |
| II/0020 | to amend sections 4.2, 4.4 and 4.8 of the SPC based on PSUR 8 evaluation. The frequency of LFT monitoring has been increased to the same frequency as the complete blood cell count. Additional side-effects related to nervous, and haemic and lymphatic systems have been added. The PL is modified accordingly. Update of Summary of Product Characteristics and Package Leaflet | 24/07/2003 | 20/10/2003 | SmPC and PL     |
| I/0019  | Qualitative change to the primary packaging. 08_Change in the qualitative composition of immediate packaging material                                                                                                                                                                                                                                                               | 16/01/2003 | 14/02/2003 | SmPC            |
| II/0018 | Update of Summary of Product Characteristics and Package Leaflet                                                                                                                                                                                                                                                                                                                    | 25/04/2002 | 18/07/2002 | SmPC and PL     |

<div style=\"page-break-after: always\"></div>

| I/0017   | 20_Extension of shelf-life as foreseen at time of authorisation                                                           | 15/01/2002   | 22/03/2002   | SmPC                             |
|----------|---------------------------------------------------------------------------------------------------------------------------|--------------|--------------|----------------------------------|
| I/0016   | 26_Changes to comply with supplements to pharmacopoeias                                                                   | 14/01/2002   | 06/03/2002   |                                  |
| I/0015   | 04_Replacement of an excipient with a comparable excipient                                                                | 14/01/2002   | 06/03/2002   |                                  |
| I/0013   | 01_Change in or addition of manufacturing site(s) for part or all of the manufacturing process                            | 19/11/2001   | 19/02/2002   | Annex II and PL                  |
| I/0012   | 30_Change in pack size for a medicinal product                                                                            | 02/10/2001   | 19/02/2002   | SmPC, Labelling and PL           |
| I/0014   | 11a_Change in the name of a manufacturer of the active substance                                                          | 05/12/2001   | 07/01/2002   |                                  |
| N/0011   | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                          | 11/09/2001   | 27/11/2001   | PL                               |
| II/0010  | Update of Summary of Product Characteristics and Package Leaflet                                                          | 29/03/2001   | 31/07/2001   | SmPC and PL                      |
| I/0009   | 26_Changes to comply with supplements to pharmacopoeias                                                                   | 02/04/2001   | 02/05/2001   |                                  |
| I/0006   | 03_Change in the name and/or address of the marketing authorisation holder 01_Change in the name of a manufacturer of the | 25/08/2000   | n/a          | SmPC, Annex II, Labelling and PL |

<div style=\"page-break-after: always\"></div>

|         | medicinal product 11a_Change in the name of a manufacturer of the active substance               |            |            |                 |
|---------|--------------------------------------------------------------------------------------------------|------------|------------|-----------------|
| I/0005  | 12_Minor change of manufacturing process of the active substance                                 | 19/07/2000 | n/a        |                 |
| N/0004  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification) | 17/05/2000 | 04/07/2000 | PL              |
| I/0003  | 12_Minor change of manufacturing process of the active substance                                 | 03/05/2000 | n/a        |                 |
| II/0002 | New safety warning                                                                               | 18/11/1999 | 24/03/2000 | SmPC and PL     |
| I/0001  | 01_Change following modification(s) of the manufacturing authorisation(s)                        | 20/09/1999 | 08/12/1999 | Annex II and PL |